JP2022531231A5 - - Google Patents
Info
- Publication number
- JP2022531231A5 JP2022531231A5 JP2021564498A JP2021564498A JP2022531231A5 JP 2022531231 A5 JP2022531231 A5 JP 2022531231A5 JP 2021564498 A JP2021564498 A JP 2021564498A JP 2021564498 A JP2021564498 A JP 2021564498A JP 2022531231 A5 JP2022531231 A5 JP 2022531231A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841748P | 2019-05-01 | 2019-05-01 | |
| US201962841753P | 2019-05-01 | 2019-05-01 | |
| US62/841,753 | 2019-05-01 | ||
| US62/841,748 | 2019-05-01 | ||
| PCT/US2020/030818 WO2020223537A1 (en) | 2019-05-01 | 2020-04-30 | Compositions and methods for the treatment of cancer using a cdb engineered t cell therapy |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022531231A JP2022531231A (ja) | 2022-07-06 |
| JP2022531231A5 true JP2022531231A5 (https=) | 2023-05-12 |
| JPWO2020223537A5 JPWO2020223537A5 (https=) | 2023-05-12 |
| JP7717619B2 JP7717619B2 (ja) | 2025-08-04 |
Family
ID=73029470
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564498A Active JP7717619B2 (ja) | 2019-05-01 | 2020-04-30 | Ｃｄ８改変ｔ細胞療法を使用するがんの治療のための組成物及び方法 |
| JP2021564500A Pending JP2022530653A (ja) | 2019-05-01 | 2020-04-30 | Ｔｅｔ２改変ｔ細胞療法を使用するがんの治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564500A Pending JP2022530653A (ja) | 2019-05-01 | 2020-04-30 | Ｔｅｔ２改変ｔ細胞療法を使用するがんの治療のための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20210085720A1 (https=) |
| EP (2) | EP3962938A4 (https=) |
| JP (2) | JP7717619B2 (https=) |
| KR (2) | KR20220004703A (https=) |
| CN (1) | CN113748127B (https=) |
| AU (2) | AU2020264484A1 (https=) |
| CA (2) | CA3151385A1 (https=) |
| IL (2) | IL287643A (https=) |
| MX (2) | MX2021013225A (https=) |
| SG (2) | SG11202111865UA (https=) |
| WO (3) | WO2020223478A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3114788A1 (en) * | 2018-09-28 | 2020-04-02 | Memorial Sloan-Kettering Cancer Center | Immunoresponsive cells expressing dominant negative fas and uses thereof |
| US12344656B2 (en) * | 2019-09-06 | 2025-07-01 | Crispr Therapeutics Ag | Genetically engineered T cells having improved persistence in culture |
| WO2021216993A1 (en) * | 2020-04-24 | 2021-10-28 | Pact Pharma, Inc. | Methods of determining gene editing efficiencies in cells |
| WO2022109277A1 (en) * | 2020-11-20 | 2022-05-27 | Pact Pharma, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFβRII ENGINEERED T CELL THERAPY |
| CA3201767A1 (en) * | 2020-12-14 | 2022-06-23 | Thomas M. Schmitt | Compositions and methods for cellular immunotherapy |
| WO2022140361A1 (en) * | 2020-12-22 | 2022-06-30 | Ludwig Institute For Cancer Research Ltd | Genetically engineered lymphocytes for adoptive cell therapy |
| US20240108652A1 (en) * | 2021-02-18 | 2024-04-04 | University Of Florida Research Foundation, Incorporated | Enhancing metabolic fitness of t cells to treat cancer |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| EP4298230A1 (en) | 2021-02-25 | 2024-01-03 | Lyell Immunopharma, Inc. | Codon-optimized nucleotide sequences encoding an ap-1 transcription factor |
| WO2022242644A1 (zh) * | 2021-05-18 | 2022-11-24 | 赛斯尔擎生物技术（上海）有限公司 | 修饰细胞的方法 |
| KR20240021216A (ko) * | 2021-06-11 | 2024-02-16 | 팩트 파마, 인크. | 세포 생성물을 감정하는 방법 |
| EP4405464A4 (en) * | 2021-09-21 | 2025-12-03 | Univ Chicago | METHODS AND COMPOSITION USING PATIENT-DERIVED AUTOLOGOUS NEOANTIGENS FOR CANCER TREATMENT |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| KR20240112376A (ko) | 2021-10-28 | 2024-07-18 | 라이엘 이뮤노파마, 인크. | c-Jun을 발현하는 세포를 배양하는 방법 |
| CN114373511B (zh) * | 2022-03-15 | 2022-08-30 | 南方医科大学南方医院 | 基于5hmC分子标志物检测的肠癌模型及肠癌模型构建方法 |
| WO2023212507A1 (en) * | 2022-04-26 | 2023-11-02 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024026490A1 (en) | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
| JP2025529540A (ja) * | 2022-09-19 | 2025-09-04 | エメンドバイオ・インコーポレイテッド | Ｔｅｔ２の両アレルノックアウト |
| CN120202302A (zh) * | 2022-09-19 | 2025-06-24 | 埃门多生物公司 | Ctla4双等位基因敲除 |
| AU2023347845A1 (en) * | 2022-09-19 | 2025-04-10 | Emendobio Inc. | Biallelic knockout of faslg |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN116179495B (zh) * | 2022-11-28 | 2025-06-06 | 上海恩凯细胞技术有限公司 | 转基因免疫细胞及其应用 |
| WO2025010272A1 (en) | 2023-07-03 | 2025-01-09 | Neoimmunetech, Inc. | Heterodimeric fc molecules and uses thereof |
| WO2025027088A1 (en) * | 2023-07-31 | 2025-02-06 | T-Knife Gmbh | An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease |
| AU2024332117A1 (en) * | 2023-08-25 | 2026-02-12 | T-Knife Gmbh | Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US20020127594A1 (en) * | 2000-06-22 | 2002-09-12 | Gearing David P. | Don-1 gene and polypeptides and uses therefor |
| US6355412B1 (en) * | 1999-07-09 | 2002-03-12 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
| US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| WO2008042814A2 (en) * | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
| US10316289B2 (en) * | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| US20160296562A1 (en) * | 2013-11-21 | 2016-10-13 | Ucl Business Plc | Cell |
| AU2015342867B2 (en) | 2014-11-06 | 2020-03-26 | University Of Maryland, Baltimore | CD8alpha and T cell receptor variants and methods of using same in modulating immune cell responses |
| CN113349159B (zh) | 2015-04-06 | 2022-11-11 | 瑞泽恩制药公司 | 非人动物中的人源化t细胞介导的免疫应答 |
| JP2018531593A (ja) | 2015-09-11 | 2018-11-01 | アジェナス インコーポレイテッド | 操作された宿主細胞及びそれらの使用方法 |
| US20180258149A1 (en) * | 2015-09-17 | 2018-09-13 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| IL297018A (en) * | 2015-12-18 | 2022-12-01 | Sangamo Therapeutics Inc | Directed cleavage of cell mhc receptor |
| CN115109120A (zh) * | 2016-04-04 | 2022-09-27 | 英蒂分子公司 | Cd8-特异性捕获剂、组合物及使用和制备方法 |
| CA3035075A1 (en) * | 2016-09-23 | 2018-03-29 | Fred Hutchinson Cancer Research Center | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof |
| KR20240024328A (ko) * | 2016-11-22 | 2024-02-23 | 알로플렉스 바이오테라퓨틱스 | 동종이형 종양 세포 백신 |
| MX2019010972A (es) * | 2017-03-15 | 2019-12-02 | Hutchinson Fred Cancer Res | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. |
| BR112019019426A2 (pt) | 2017-03-22 | 2020-05-26 | Novartis Ag | Biomarcadores e terapias com células t car com eficácia intensificada |
| WO2018175636A2 (en) * | 2017-03-22 | 2018-09-27 | Novartis Ag | Compositions and methods for immunooncology |
| US11512287B2 (en) * | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| US11352389B2 (en) * | 2017-06-30 | 2022-06-07 | Academisch Ziekenhuis Leiden (H.O.D.N. Leids Universitair Medisch Centrum) | Treatment of haematological malignancies |
| AU2018329741B2 (en) * | 2017-09-08 | 2025-02-20 | Poseida Therapeutics, Inc. | Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression |
| MX2020004541A (es) * | 2017-10-30 | 2021-04-12 | Pact Pharma Inc | Edicion de genes de celulas primarias. |
| US20200338128A1 (en) * | 2018-01-05 | 2020-10-29 | Gencyte Therapeutics, Inc. | Precision molecular adaptor system for car-t immunotherapy |
| SG11202009761YA (en) | 2018-04-02 | 2020-10-29 | Pact Pharma Inc | Peptide-mhc compacts |
| CN113166778A (zh) * | 2018-09-05 | 2021-07-23 | 葛兰素史克知识产权开发有限公司 | T细胞修饰 |
| GB201819540D0 (en) * | 2018-11-30 | 2019-01-16 | Adaptimmune Ltd | T cell modification |
| IL316576A (en) | 2019-02-12 | 2024-12-01 | Pact Pharma Inc | Preparations and methods for identifying antigen-specific T cells |
| WO2020243134A1 (en) * | 2019-05-27 | 2020-12-03 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
-
2020
- 2020-04-30 EP EP20798669.6A patent/EP3962938A4/en active Pending
- 2020-04-30 SG SG11202111865UA patent/SG11202111865UA/en unknown
- 2020-04-30 CA CA3151385A patent/CA3151385A1/en active Pending
- 2020-04-30 KR KR1020217038746A patent/KR20220004703A/ko active Pending
- 2020-04-30 SG SG11202111532SA patent/SG11202111532SA/en unknown
- 2020-04-30 JP JP2021564498A patent/JP7717619B2/ja active Active
- 2020-04-30 EP EP20798347.9A patent/EP3953379A4/en active Pending
- 2020-04-30 WO PCT/US2020/030704 patent/WO2020223478A1/en not_active Ceased
- 2020-04-30 AU AU2020264484A patent/AU2020264484A1/en active Pending
- 2020-04-30 WO PCT/US2020/030818 patent/WO2020223537A1/en not_active Ceased
- 2020-04-30 MX MX2021013225A patent/MX2021013225A/es unknown
- 2020-04-30 CA CA3136740A patent/CA3136740A1/en active Pending
- 2020-04-30 JP JP2021564500A patent/JP2022530653A/ja active Pending
- 2020-04-30 AU AU2020266579A patent/AU2020266579A1/en not_active Abandoned
- 2020-04-30 CN CN202080032593.3A patent/CN113748127B/zh active Active
- 2020-04-30 KR KR1020217038747A patent/KR20220005050A/ko not_active Withdrawn
- 2020-04-30 MX MX2021013218A patent/MX2021013218A/es unknown
- 2020-05-01 WO PCT/US2020/031007 patent/WO2020223625A1/en not_active Ceased
- 2020-11-16 US US17/099,140 patent/US20210085720A1/en not_active Abandoned
- 2020-11-20 US US17/100,223 patent/US11304978B2/en active Active
-
2021
- 2021-10-27 IL IL287643A patent/IL287643A/en unknown
- 2021-10-27 IL IL287639A patent/IL287639A/en unknown
-
2022
- 2022-03-10 US US17/691,565 patent/US12247061B2/en active Active
-
2025
- 2025-02-04 US US19/044,972 patent/US20260001931A1/en active Pending